Radiation and chemotherapy after pancreatic cancer surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether combining radiation therapy with chemotherapy (called the GX regimen) after pancreatic cancer surgery helps prevent cancer from returning in patients with high-risk features. The study aims to see if this combination treatment improves outcomes compared to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had pancreatic cancer surgery with at least one high-risk feature (such as incomplete tumor removal, lymph node involvement, nerve/blood vessel invasion, poorly differentiated cancer, or tumor larger than 4 cm)
- Your cancer must not have spread to distant organs, and imaging after surgery must show no new cancer growth
- You must be between 18 and 75 years old with good overall health and performance status (able to do light activities)
- Your blood counts, liver function, and kidney function must be adequate to tolerate treatment
- You cannot have received chemotherapy or radiation before your surgery, and you must not have other active cancers
- You must be able to start treatment within 12 weeks after surgery and have no serious complications from the operation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tumor vaccine (XH001) combined with standard chemotherapy after surgery for pancreatic cancer. The goal is to lower the chance of the cancer coming back.
This trial tests a combination of two drugs (nimotuzumab and GX) given after surgery for pancreatic cancer. The goal is to see if this treatment helps prevent the cancer from coming back. It is for people who had their entire tumor removed and have not had prior cancer treatment.
This trial compares adding radiation to chemotherapy versus chemotherapy alone after surgery for pancreatic cancer. It is for people whose cancer had certain high-risk features found during surgery, and who have not yet started additional treatment.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
This trial tests a new chemotherapy combination (HR070803 plus two other drugs) given after surgery to see if it prevents pancreatic cancer from coming back better than the current standard treatment.
This trial tests a combination of four drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin, and adebrelimab) given with radiation therapy before surgery for pancreatic cancer that can be surgically removed or is borderline removable. The goal is to shrink the tumor and improve the chances of successful surgery.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.